Published on 5 Apr 2024 on Benzinga

Moderna's Vaccines Day 2024: A Glimpse into the Future of Infectious Disease Prevention - Moderna...

Moderna, Inc. MRNA recently hosted its fourth annual Vaccines Day, offering a deep dive into the company's expanding infectious disease vaccines portfolio. President Stephen Hoge opened the event, highlighting the progress Moderna has made in developing a diverse array of vaccines targeting various populations and pathogens, including viruses and bacterial proteins.

The event showcased Moderna's robust pipeline, with 28 vaccines in development, and provided updates on key programs such as the cytomegalovirus (CMV) vaccine, which has completed enrollment for a global clinical trial. The company is now in the follow-up phase, awaiting confirmation of primary CMV cases. The trial's design aims to demonstrate the vaccine's efficacy, safety, and immunogenicity, with a particular focus on women and adolescents who frequently contact young children, the primary vector for CMV transmission.